UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo

Cancer Immunology, Immunotherapy, 2021-06, Vol.70 (6), p.1569-1581

2021

Volltextzugriff (PDF)

Determinants of CPT-11 and SN-38 activities in human lung cancer cells

British journal of cancer, 1998-06, Vol.77 (12), p.2171-2176

1998

Volltextzugriff (PDF)

PO-434 AT1413 antibody derived from a cured AML patient recognisesa unique sialylated CD43 epitope shared by AML, MDS and melanoma cells

ESMO open, 2018-07, Vol.3 (Suppl 2), p.A192-A192

2018

Volltextzugriff (PDF)

RNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNA

Cell, 2007-12, Vol.131 (7), p.1273-1286

2007

Volltextzugriff (PDF)

11P snRNP200 reactive antibodies isolated from multiple AML patients show promise for targeted therapy

ESMO open, 2024-02, Vol.9, p.102266, Article 102266

2024

Volltextzugriff (PDF)

14P Kling-Select and Kling-Evolve: A universal platform interrogating blood and tumor-associated B cell repertoires enabling unbiased discovery of therapeutic targets and antibodies from patients

ESMO open, 2024-02, Vol.9, p.102381, Article 102381

2024

Volltextzugriff (PDF)

12P KBA1413, an antibody derived from a cured AML patient, recognizes a unique CD43 glycoform shared by AML, MDS and solid cancer cells

ESMO open, 2024-02, Vol.9, p.102267, Article 102267

2024

Volltextzugriff (PDF)

580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection

Annals of oncology, 2020-09, Vol.31, p.S492-S492

2020

Volltextzugriff (PDF)

24 Cancerous microRNAs and regulatory RNA binding proteins

European journal of cancer supplements, 2010, Vol.8 (5), p.7-7

2010

Volltextzugriff (PDF)

A phase I study of monohydroxyethylrutoside in healthy volunteers

Cancer chemotherapy and pharmacology, 2006-05, Vol.57 (5), p.678-684

2006

Volltextzugriff (PDF)

PS971 AT1413 ANTIBODY DERIVED FROM A CURED AML PATIENT RECOGNIZES A UNIQUE CD43 EPITOPE SHARED BY AML, MDS AND MELANOMA AND HAS IN VIVO ACTIVITY AS UNMODIFIED ANTIBODY AND AS BISPECIFIC T CELL ENGAGER

HemaSphere, 2019-06, Vol.3 (S1), p.437-438

2019

Volltextzugriff (PDF)

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1657-1667

Kuenen, B. C.

2002

Volltextzugriff (PDF)

Continuous administration of irinotecan by hepatic arterial infusion: A Phase I and pharmacokinetic study

Clinical cancer research, 2002-02, Vol.8 (2), p.405-412

2002

Volltextzugriff (PDF)

Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection

Journal of chromatography. B, Biomedical sciences and applications, 2001-06, Vol.757 (1), p.191-196

2001

Volltextzugriff (PDF)

High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma

Journal of chromatography. B, Biomedical sciences and applications, 2001-03, Vol.752 (1), p.115-121

2001

Volltextzugriff (PDF)

The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG

Cancer chemotherapy and pharmacology, 2003-06, Vol.51 (6), p.499-504

2003

Volltextzugriff (PDF)

Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

Cancer chemotherapy and pharmacology, 2003-11, Vol.52 (5), p.371-376

2003

Volltextzugriff (PDF)

The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice

Cancer chemotherapy and pharmacology, 2003-04, Vol.51 (4), p.306-310

2003

Volltextzugriff (PDF)

Appraisal of Asymptotics in Electromagnetic Field Calculations

Scientific Computing in Electrical Engineering, p.137-144

Volltextzugriff (PDF)

miR-148 targets human DNMT3b protein coding region

RNA (Cambridge), 2008-05, Vol.14 (5), p.872-877

2008

Volltextzugriff (PDF)

Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells

Scientific reports, 2022-08, Vol.12 (1), p.13940-13940, Article 13940

2022

Volltextzugriff (PDF)

Sexual dysfunction in young women with breast cancer

Supportive care in cancer, 2013, Vol.21 (1), p.271-280

2013

Volltextzugriff (PDF)

Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients

Breast cancer research and treatment, 2024-02, Vol.204 (1), p.27-37

2024

Volltextzugriff (PDF)

Subjective sexual well-being and sexual behavior in young women with breast cancer

Supportive care in cancer, 2013-07, Vol.21 (7), p.1993-2005

2013

Volltextzugriff (PDF)

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)
Buchkapitel
(1)

Sprache

Englisch
(37)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo

Determinants of CPT-11 and SN-38 activities in human lung cancer cells

PO-434 AT1413 antibody derived from a cured AML patient recognisesa unique sialylated CD43 epitope shared by AML, MDS and melanoma cells

RNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNA

11P snRNP200 reactive antibodies isolated from multiple AML patients show promise for targeted therapy

14P Kling-Select and Kling-Evolve: A universal platform interrogating blood and tumor-associated B cell repertoires enabling unbiased discovery of therapeutic targets and antibodies from patients

12P KBA1413, an antibody derived from a cured AML patient, recognizes a unique CD43 glycoform shared by AML, MDS and solid cancer cells

580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection

24 Cancerous microRNAs and regulatory RNA binding proteins

A phase I study of monohydroxyethylrutoside in healthy volunteers

PS971 AT1413 ANTIBODY DERIVED FROM A CURED AML PATIENT RECOGNIZES A UNIQUE CD43 EPITOPE SHARED BY AML, MDS AND MELANOMA AND HAS IN VIVO ACTIVITY AS UNMODIFIED ANTIBODY AND AS BISPECIFIC T CELL ENGAGER

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Continuous administration of irinotecan by hepatic arterial infusion: A Phase I and pharmacokinetic study

Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection

High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma

The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG

Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice

Appraisal of Asymptotics in Electromagnetic Field Calculations

miR-148 targets human DNMT3b protein coding region

Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells

Sexual dysfunction in young women with breast cancer

Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients

Subjective sexual well-being and sexual behavior in young women with breast cancer

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Suchergebnisse filtern